Pushing AR toward better outcomes in breast and prostate cancers

每年有6000澳大利亚人死于乳腺癌和前列腺癌。这两种癌症惊人地相似，都是由已经变坏的激素受体驱动的。目前的治疗方法旨在根除受体。虽然常常有效，但治疗耐药性是常见的，并会导致致命的疾病。我们的目标是开发新的、毒性较低的治疗方法，在不破坏受体行为的情况下，将受体的行为从好变坏。这应该会提高生活质量，同时防止抗药性和生命损失。

Breast and prostate cancers kill >6000 Australians each year. These cancers are strikingly similar, both driven by hormone receptors that have ‘gone bad’. Current therapies aim to eradicate the receptors. While often effective, therapeutic resistance is common and results in fatal disease. We aim to develop new, less toxic treatments that switch receptor behaviour from good to bad, without destroying them. This should improve quality of life, while preventing drug resistance and loss of lives.